N
Nuevocor
Operates as a preclinical-stage biotech company
About Nuevocor
Nuevocor is a biotechnology startup that operates in the field of genetic medicine. The company's primary focus is on the development of treatments for lamin dilated cardiomyopathy, a heart condition that can lead to heart failure. Nuevocor's lead program, NVC-001, is a genetic medicine designed to treat this condition.
The company's unique approach to treatment involves the use of their proprietary PrOSIA mechanobiology platform. This platform allows Nuevocor to design genetic medicines that address the biomechanical root cause of diseases, rather than just treating single gene mutations. This is a significant departure from traditional gene therapy and could potentially benefit a larger number of patients.
Nuevocor's business model is based on the research, development, and commercialization of these genetic medicines. The company's primary clients are patients suffering from diseases that can be treated with their innovative approach. The market for such treatments is vast, given the prevalence of genetic diseases and the limitations of current treatment options.
The company generates revenue through the sale of its genetic medicines. As the company's treatments are still in the development stage, it is likely that they also rely on funding from investors and grants for research and development.
Nuevocor positions itself at the forefront of a new generation of genetic medicine companies. Their innovative pathway-centric approach could potentially revolutionize the treatment of genetic diseases, making them a company to watch in the biotech sector.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | May 2025 | $45M | $180M | Boehringer Ingelheim Venture Fund · Kurma Partners · EDBI · Highlight Capital | ↗ |
| EARLY VCOther financing | Nov 2022 | $12M | $120M | EDBI · Boehringer Ingelheim Venture Fund · Seeds Capital · Everjoy Fortune | ↗ |
Growth signals
Latest recorded traffic for Nuevocor is 2.9K monthly website visits, up 559.1% over the last three months. Nuevocor's team declined 6.5% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Nuevocor in the Singapore ecosystem
The Nuevocor office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A11 investors entered at this stage
Boehringer Ingelheim Venture Fund
EVX Ventures
EDBI
Seeds Capital- EFEverjoy Fortune
ZORA Ventures
Hyfinity Investments
Kurma Partners
Angelini Ventures
Highlight Capital
ClavystBio
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Nuevocor on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Nuevocor’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







